S100B

Across TCGA pan-cancer cohorts, S100B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated S100B data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher S100B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated S100B expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, COAD, and LSCC are the cancer types where S100B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.850	0.682	<.001	29	view →
COAD	DFS	Median	III,IV	0.835	1.000	.033	12	view →
LSCC	OS	Tertile	III,IV	1.000	0.687	.019	7	view →
CCRCC	DFS	Median	II,III,IV	0.391	0.762	.036	4	view →
GBM	OS	Quartile	All	0.509	0.865	.020	3	view →
LUAD	DFS	Quartile	All	0.774	0.491	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

S100B–PDAC (DFS)

Open the PDAC breakdown →